About


Who we are


We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47.

Our Technology


DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells.

Experienced leadership


Helix is led by an experienced Management team with excellent pharmaceutical development expertise and proven business skills. The group is committed in developing novel medicines through DOS47 platform technology.

Management


Image

Sławomir Majewski

Interim CEO


MD, PhD
Vice Rector of the Medical University of Warsaw, Corresponding Member of the Polish Academy of Science

Image

Artur Gabor

CEO


Mr. Artur Gabor was appointed to Helix Board of Directors in February 2019. He is also serving as a member of the Supervisory Board of Asseco Poland S.A. He has previously served as Chairman - Supervisory Board at Getin Bank S.A., member of the Supervisory Board at GE Capital Bank S.A. in Poland, member of the Supervisory Board and Chairman of Audit Committee at Orlen S.A., Director- Financial Sector at IBM Poland , Managing Director - Poland at Credit Lyonnais Investment Banking Group, Director- Merger & Acquisitions at General Electric Capital SNC. He also serves as a member of Advisory Committee at American Chamber of Commerce in Poland. Mr.Gabor received an undergraduate degree from University College London and graduate degree from University in Warsaw. In 2015 he successfully completed AMP- Advanced Management Program at IESE Business School and Value Creation Trough Effective Boards at Harvard Business School / IESE Business School.

Image

Hatem Kawar

CFO


Image

Namrata Malhotra

Corporate Secretary


Image

Christof Bohler

Advisor to the BoD


Image

Atul Deshpande

Advisor to the BoD


Board of directors


Image

Artur Gabor

CEO and Director


Founder Gabor & Gabor
Supervisory Board Chairman – Sfinks Polska S.A. and Grupa LEW S.A.

Image

Sławomir Majewski


MD, PhD
Vice Rector of the Medical University of Warsaw, Corresponding Member of the Polish Academy of Science

Image

Jerzy Leszczyński

Board Member


Founder Gabor & Gabor
Supervisory Board Chairman – Sfinks Polska S.A. and Grupa LEW S.A.

Image

Ireneusz Fafara


Over 30 years of experience in financial and industrial sector. Former General Director of the Supervisory Board of ORLEN Lietuva.

Image

Christopher Maceijewski

Board Member


Founder Gabor & Gabor
Supervisory Board Chairman – Sfinks Polska S.A. and Grupa LEW S.A.

Image

Ireneusz Fafara


Over 30 years of experience in financial and industrial sector. Former General Director of the Supervisory Board of ORLEN Lietuva.

Image

Jacek Antas

Board Member and Chair, Audit Committee


Founder Gabor & Gabor
Supervisory Board Chairman – Sfinks Polska S.A. and Grupa LEW S.A.

Image

Ireneusz Fafara


Over 30 years of experience in financial and industrial sector. Former General Director of the Supervisory Board of ORLEN Lietuva.

Image

Adam Uszpolewicz


Founder Gabor & Gabor
Supervisory Board Chairman – Sfinks Polska S.A. and Grupa LEW S.A.

Image

Ireneusz Fafara


Over 30 years of experience in financial and industrial sector. Former General Director of the Supervisory Board of ORLEN Lietuva.

Scientific and Strategic Advisory Board(SSAB)


Image

Robert Gillies


Dr. Robert Gillies holds the Martin Silbiger Endowed Chair and is Chair of the Department of Cancer Physiology and Vice-Chair (Research) of the Department of Radiology, H. Lee Moffitt Cancer Center and Research Institute; and Professor Emeritus, Departments of Radiology and Biomedical Engineering, College of Medicine University of Arizona. He is past president of the Society for Molecular Imaging and has served on numerous grant review panels for the NIH and the DoD, consulting on cancer physiology and imaging. Dr. Gillies is an expert in tumor acidity and has published extensively in this area of research.

Image

Frank Gary Renshaw


Dr. Renshaw is the Chief Medical Officer of Zhejiang DTRM Biopharma Co. Ltd. Previous roles included Medical Oncology Director at Eisai; Global Executive Director Level II, Oncology and Hematology R&D at Celgene Corporate; Executive Director at Celsion Corporation and Global Clinical Lead; and Clinical Pharm Lead at Bayer Health Care Corporation. Dr. Renshaw participates in a number of oncology industry committees and task forces